This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The product will be marketed by Dr. Reddy's Laboratories Inc.
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The company will respond to the US FDA within the stipulated timelines
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Subscribe To Our Newsletter & Stay Updated
